Project

ECARA

Completed ยท 2017 until 2019

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2017
End Date
2019
Financing
Industry
Study Design
Describe lipid parameters in patients on Evolocumab at baseline and over 12 months in an observational real world setting. Maintenance of LDL-c reduction over the study period serves as surrogate for persistence with therapy and informs us about the utility of a bi-weekly or monthly SC application in clinical practice
Brief description/objective

Explore Clinical Utility of Evolocumab in Combination with
an e-Health System: Swiss Prospective Observational
Study in Patients with clinical Atherosclerotic
Cardiovascular Disease (ASCVD) (ECARA)